Form 4: Ventas CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Ventas Chairman and CEO Debra A. Cafaro sold 219,515 shares of common stock, acquired through option exercises, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Debra A. Cafaro, Chairman and CEO of Ventas, Inc. (VTR), reported transactions involving the exercise of stock options and the subsequent sale of common stock.
• On October 20, 2025, Ms. Cafaro exercised 185,283 stock options at an exercise price of $62.22 per share.
• Concurrently, 185,283 shares of common stock were sold at a weighted average price of $71.3227 per share, with prices ranging from $71.00 to $71.50.
• Additionally, on October 20, 2025, Ms. Cafaro exercised 34,232 stock options at an exercise price of $65.45 per share.
• Simultaneously, 34,232 shares of common stock were sold at a weighted average price of $71.3227 per share, within the same price range.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan established by Ms. Cafaro on March 28, 2024.
• Following these transactions, Ms. Cafaro beneficially owns 1,145,695 shares of Ventas Common Stock directly.
• She also holds 937,132 unexercised stock options to purchase shares of Ventas Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves an insider sale, the transactions were pre-planned under a Rule 10b5-1 plan, which mitigates negative signaling. The executive also retains substantial equity and option holdings, indicating continued alignment with company performance.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled liquidity event rather than a reaction to recent company performance or market conditions.
• The executive monetized fully vested options, which is a common practice for long-tenured executives to manage personal finances and diversify holdings.
• The executive retains a significant beneficial ownership of 1,145,695 shares of common stock and 937,132 unexercised options, demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of conviction in the stock's immediate future upside, although this is often mitigated by the pre-planned nature.

Risks

• The filing notes that some options were scheduled to expire within 7 to 15 months, indicating a potential risk of forfeiture if not exercised, which these transactions addressed.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The transactions involved the exercise of fully vested options scheduled to expire in the next 15 months and 7 months, respectively, and the sale of the underlying shares net of the exercise price and taxes.
• All transactions were executed pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on March 28, 2024.

Industry Context

This filing is specific to an insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: May observe the executive's sale, but the pre-arranged nature of the 10b5-1 plan typically reduces concerns about a lack of confidence. The executive's continued significant holdings maintain alignment.
• Employees: No direct impact from this filing.
• Customers: No direct impact from this filing.
• Suppliers: No direct impact from this filing.
• Creditors: No direct impact from this filing.

Key Dates

Recommendation

The filing details a pre-arranged sale of shares by the CEO, acquired through the exercise of vested stock options. This is a planned liquidity event and not indicative of a change in the company's fundamental outlook or the executive's long-term conviction, as a significant number of shares and options are still held. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Ventas, VTR, Debra Cafaro, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, CEO, Healthcare REIT, Real Estate Investment Trust